Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART

Abstract

The objective of the study was to determine the association of neurocognitive impairment with health-related quality of life (HRQoL) in patients receiving highly active antiretroviral therapy (HAART). Seventy subjects were cross-sectionally analysed with a standardized neuropsychological test battery and a questionnaire including an Italian translation of the MOS-HIV Health Survey. The presence of neurocognitive impairment was significantly associated with lower HRQoL scores: pain ( P = 0.03), physical functioning ( P = 0.01), role functioning ( P = 0.01), social functioning ( P = 0.029), mental health ( P = 0.001), energy ( P = 0.036), health distress ( P = 0.002), cognitive functioning ( P = 0.05), current health perception ( P <0.001), physical health summary score (PHS) ( P = 0.005), mental health summary score (MHS) ( P = 0.002). Years of education (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.65-0.96), PHS (OR 0.71; 95% CI 0.54-0.95) and MHS (OR 0.67; 95% CI 0.51-0.88) were also associated with cognitive impairment. Neurocognitive impairment in patients receiving HAART was associated with reduced HRQoL. Identifying cognitive impairment may provide motivation for additional treatment to help patients to compensate for deficits in functioning.